| Ytd | -30.35% | |
| 1y | -48.85% |
| Open | 1.59 | Prev Close | 1.59 | Low | 1.55 | High | 1.61 | Mkt Cap | 536.32M |
| Vol | 169.99K | Avg Vol | 1.12M | EPS | -0.53 | P/E | -3.01 | Forward P/E | -5.33 |
| Beta | 1.61 | Short Ratio | 3.72 | Inst. Own | 30.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 1.75 | 200-d Avg | 2.16 | 1yr Est | 5.83 |
PROK News
Stocks up, Dow Jones +100 points. AEVEX Corp shares rose 11.8% on $50m Air Force contract. Other big
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Che
HC Wainwright & Co. analyst Joseph Pantginis reiterates ProKidney (NASDAQ:PROK) with a Buy an
ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which met the analyst consens
WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or
Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report)
WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”
Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have earned a consensus rating of "Modera
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which missed the analyst cons
ProKidney (NASDAQ: PROK - Get Free Report) will likely be releasing its Q4 2025 results before the m
PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA al
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o
HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on ProKidney (NASDAQ:PROK) wi
Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have been given a consensus recommendatio
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consen
WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o
WINSTON-SALEM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o
Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report
WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o
WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o
Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay
I rate ProKidney a buy due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA ali
ProKidney Corp. (NASDAQ:PROK ) Citi's Biopharma Back to School Conference September 3, 2025 10:30 AM
During the session on Thursday, 461 stocks hit new 52-week lows.